Focused On-demand Library for Double-stranded RNA-specific adenosine deaminase

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P55265

UPID:
DSRAD_HUMAN

ALTERNATIVE NAMES:
136 kDa double-stranded RNA-binding protein; Interferon-inducible protein 4; K88DSRBP

ALTERNATIVE UPACC:
P55265; B1AQQ9; B1AQR0; D3DV76; O15223; O43859; O43860; Q9BYM3; Q9BYM4

BACKGROUND:
Double-stranded RNA-specific adenosine deaminase, with aliases such as 136 kDa double-stranded RNA-binding protein, is pivotal in A-to-I RNA editing. This enzyme catalyzes the conversion of adenosine to inosine in dsRNA, a process vital for gene expression modulation, mRNA translation, and RNA stability. It edits both viral and cellular RNAs, affecting the amino acid sequence of proteins, splice site recognition, and RNA virus genome stability.

THERAPEUTIC SIGNIFICANCE:
This protein's involvement in conditions like Dyschromatosis symmetrica hereditaria and Aicardi-Goutieres syndrome 6 underscores its therapeutic relevance. Its role in RNA editing and interaction with viral and cellular RNAs presents it as a promising target for drug discovery, offering new avenues for treating genetic and infectious diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.